Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1996 Sep;61(3):251–258. doi: 10.1136/jnnp.61.3.251

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

C Pozzilli 1, S Bastianello 1, T Koudriavtseva 1, C Gasperini 1, A Bozzao 1, E Millefiorini 1, S Galgani 1, C Buttinelli 1, G Perciaccante 1, G Piazza 1, L Bozzao 1, C Fieschi 1
PMCID: PMC486547  PMID: 8795595

Abstract

OBJECTIVE: To evaluate whether recombinant human interferon-beta-1a significantly affects disease activity as measured by a reduction in the number and volume of Gd enhancing lesions on monthly MRI. The study also evaluated the effect on six-monthly T2 weighted abnormality and relapse frequency. METHODS: After a baseline scan and a six month pretreatment period, 68 patients were randomly assigned to receive either 3 MIU or 9 MIU of interferon-beta-1a by subcutaneous injection three times a week for six months. All patients were examined by Gd enhanced MRI every month in both pretreatment and treatment periods. The evaluation of Gd enhancing lesions was performed blind at the end of the study. RESULTS: The mean number of Gd enhancing lesions was higher during the pretreatment period than during treatment. This difference was statistically significant for the two different dose subgroups (3.5 v 1.8, P < 0.001 for the 3 MIU group and 2.4 v 0.9, P < 0.001 for the 9 MIU group, corresponding to a reduction of 49% and 64% respectively). The mean volume of Gd enhancing lesions also significantly decreased by 61% (3 MIU group) and 73% (9 MIU group). These reductions were evident only after the first month of treatment. The six-monthly rate of new lesions as seen in T2 weighted images showed a similar trend of reduction with treatment (65% and 70% respectively). Lesion volume on T2 scans significantly increased during the pretreatment period whereas it remained almost stable during the treatment period in both groups. Clinical relapse rate was significantly reduced by treatment (53% for the 3 MIU group, P < 0.001; 69% for the 9 MIU group, P < 0.001). CONCLUSION: Interferon-beta-1a seemed effective in reducing disease activity in relapsing-remitting multiple sclerosis at both the doses used.

Full text

PDF
255

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barkhof F., Hommes O. R., Scheltens P., Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991 Aug;41(8):1219–1222. doi: 10.1212/wnl.41.8.1219. [DOI] [PubMed] [Google Scholar]
  2. Barkhof F., Tas M. W., Frequin S. T., Scheltens P., Hommes O. R., Nauta J. J., Valk J. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology. 1994 Jul;36(5):382–387. doi: 10.1007/BF00612124. [DOI] [PubMed] [Google Scholar]
  3. Bastianello S., Pozzilli C., Bernardi S., Bozzao L., Fantozzi L. M., Buttinelli C., Fieschi C. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology. 1990 Apr;40(4):591–595. doi: 10.1212/wnl.40.4.591. [DOI] [PubMed] [Google Scholar]
  4. Gonzalez-Scarano F., Grossman R. I., Galetta S., Atlas S. W., Silberberg D. H. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol. 1987 Mar;21(3):300–306. doi: 10.1002/ana.410210312. [DOI] [PubMed] [Google Scholar]
  5. Harris J. O., Frank J. A., Patronas N., McFarlin D. E., McFarland H. F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991 May;29(5):548–555. doi: 10.1002/ana.410290515. [DOI] [PubMed] [Google Scholar]
  6. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  7. Jacobs L., Johnson K. P. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol. 1994 Dec;51(12):1245–1252. doi: 10.1001/archneur.1994.00540240089022. [DOI] [PubMed] [Google Scholar]
  8. Khoury S. J., Guttmann C. R., Orav E. J., Hohol M. J., Ahn S. S., Hsu L., Kikinis R., Mackin G. A., Jolesz F. A., Weiner H. L. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 1994 Nov;44(11):2120–2124. doi: 10.1212/wnl.44.11.2120. [DOI] [PubMed] [Google Scholar]
  9. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  10. Liberati A. M., Horisberger M. A., Palmisano L., Astolfi S., Nastari A., Mechati S., Villa A., Mancini S., Arzano S., Grignani F. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta. J Interferon Res. 1992 Oct;12(5):329–336. doi: 10.1089/jir.1992.12.329. [DOI] [PubMed] [Google Scholar]
  11. McFarland H. F., Frank J. A., Albert P. S., Smith M. E., Martin R., Harris J. O., Patronas N., Maloni H., McFarlin D. E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 Dec;32(6):758–766. doi: 10.1002/ana.410320609. [DOI] [PubMed] [Google Scholar]
  12. Miller D. H., Barkhof F., Berry I., Kappos L., Scotti G., Thompson A. J. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 1991 Aug;54(8):683–688. doi: 10.1136/jnnp.54.8.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miller D. H., Barkhof F., Nauta J. J. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain. 1993 Oct;116(Pt 5):1077–1094. doi: 10.1093/brain/116.5.1077. [DOI] [PubMed] [Google Scholar]
  14. Miller D. H., Rudge P., Johnson G., Kendall B. E., Macmanus D. G., Moseley I. F., Barnes D., McDonald W. I. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988 Aug;111(Pt 4):927–939. doi: 10.1093/brain/111.4.927. [DOI] [PubMed] [Google Scholar]
  15. Miller D. H., Thompson A. J., Morrissey S. P., MacManus D. G., Moore S. G., Kendall B. E., Moseley I. F., McDonald W. I. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):450–453. doi: 10.1136/jnnp.55.6.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nauta J. J., Thompson A. J., Barkhof F., Miller D. H. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci. 1994 Mar;122(1):6–14. doi: 10.1016/0022-510x(94)90045-0. [DOI] [PubMed] [Google Scholar]
  17. Paty D. W., Li D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
  18. Rudge P., Miller D., Crimlisk H., Thorpe J. Does interferon beta cause initial exacerbation of multiple sclerosis? Lancet. 1995 Mar 4;345(8949):580–580. doi: 10.1016/s0140-6736(95)90486-7. [DOI] [PubMed] [Google Scholar]
  19. Smith M. E., Stone L. A., Albert P. S., Frank J. A., Martin R., Armstrong M., Maloni H., McFarlin D. E., McFarland H. F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993 May;33(5):480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]
  20. Stone L. A., Frank J. A., Albert P. S., Bash C., Smith M. E., Maloni H., McFarland H. F. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995 May;37(5):611–619. doi: 10.1002/ana.410370511. [DOI] [PubMed] [Google Scholar]
  21. Thompson A. J., Miller D., Youl B., MacManus D., Moore S., Kingsley D., Kendall B., Feinstein A., McDonald W. I. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992 Jan;42(1):60–63. doi: 10.1212/wnl.42.1.60. [DOI] [PubMed] [Google Scholar]
  22. Wicks D. A., Tofts P. S., Miller D. H., du Boulay G. H., Feinstein A., Sacares R. P., Harvey I., Brenner R., McDonald W. I. Volume measurement of multiple sclerosis lesions with magnetic resonance images. A preliminary study. Neuroradiology. 1992;34(6):475–479. doi: 10.1007/BF00598953. [DOI] [PubMed] [Google Scholar]
  23. Wiebe S., Lee D. H., Karlik S. J., Hopkins M., Vandervoort M. K., Wong C. J., Hewitt L., Rice G. P., Ebers G. C., Noseworthy J. H. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol. 1992 Nov;32(5):643–650. doi: 10.1002/ana.410320507. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES